Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer (Stage III): early-phase trial registry
7 of 9 indexed Non-Small Cell Lung Cancer (Stage III) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 7 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer (Stage III): 9 US clinical trials tracked, 7 recruiting.
Non-Small Cell Lung Cancer (Stage III) is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Wake Forest University Health Sciences, running 2 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-stage-iii
OPEN 7 | RECR 78% | LATE 1 | EARLY 8 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Colorectal Carcinoma (78% recruiting · 9 trials)
Non-Small Cell Lung Cancer (Stage III) lists 7 open slots (78% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer (Stage III) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer (Stage III) is recruiting above its size-band peers.
7 of 9 indexed trials (77.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-Small Cell Lung Cancer (Stage III) research.
Wake Forest University Health Sciences accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Small Cell Lung Cancer (Stage III) trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer (Stage III) research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Genelux Corporation
NCT06463665
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
Case Comprehensive Cancer Center
NCT07104630
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
NCT04585477
HEARTS Trial for Thoracic Cancers
University of Wisconsin, Madison
NCT07132918
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
NCT05692635
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Wake Forest University Health Sciences
NCT05696782
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
Georgetown University
NCT06449313
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
AstraZeneca
NCT03521154
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT04716946
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer (Stage III) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer (Stage III) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer (Stage III) page
9 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Non-Small Cell Lung Cancer (Stage III) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Wake Forest University Health Sciences sponsors the most Non-Small Cell Lung Cancer (Stage III) trials on record, review their full trial history before evaluating a specific study. See Wake Forest University Health Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer (Stage III) condition card totals 9 registered trials; most-linked intervention Durvalumab; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.